POPULARITY
In this episode, I explore the pathology of Parkinson's disease and other neurodegenerative disorders with Prof. Alberto Espay, co-author of the book titled Brain Fables
Brain Talk | Being Patient for Alzheimer's & dementia patients & caregivers
High-tech treatments for neurodegenerative diseases are on the horizon. In fact, some patients already have brain implants that help address their symptoms through “reprogramming the brain.” Hear from one patient and his doctor about the real-life story behind this innovative new treatment for Parkinson's. Speaker, author, and Parkinson's Disease advocate Benjamin Stecher and neurologist Dr. Alfonso Fasano, join Being Patient live talks to discuss their upcoming book on just this topic, Reprogramming the Brain. The upcoming book, traces the experience of Stecher and his doctor Fasano's 2021 decision to surgically implant two six-inch-long metal alloy spikes all the way through his brain. With the patient and doctor writing about the experience and what was to come afterward, the upcoming book will serve as a guide for the future of the brain and neuromodulation. Stecher, who was diagnosed with Parkinson's disease at age 29, speaks regularly at academic centers and biotech companies about neurodegenerative diseases, research advocacy, and healthcare. The founder of Tomorrow Edition, he is a patient advisor to several organizations, including the Toronto Western Hospital Movement Disorder Clinic and Rune Labs. In addition to his upcoming book, he also co-wrote Brain Fables with Alberto Espay, published by Cambridge University Press. Fasano, who holds the Chair in Neuromodulation at the University of Toronto and University Health Network, is also a Professor in the Department of Medicine at the University of Toronto. In addition, he is staff neurologist and co-director of the Surgical Program for Movement Disorders at Toronto Western Hospital, staff neurologist at the Hospital of Sick Children in Toronto, and clinician investigator at the Krembil Research Institute and KITE – Toronto Rehabilitation Hospital. His work focuses on the treatment of movement disorders with advanced technology, pathophysiology, and treatment of tremor and gait disorders.
Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. This episode features an in-depth dive into the recent approval of lecanemab (Leqembi; Eisai) for Alzheimer disease and the ongoing debate about its potential benefit, the amyloid-targeting class of medicines, and the communication of data. Featured in this episode is commentary from 2 experts in neurology clinical care: Anton P. Porsteinsson, MD, the William B. and Sheila Konar Professor of Psychiatry, Neurology, Neuroscience, and Medicine, and the director of the Alzheimer's Disease Care, Research and Education Program at the University of Rochester School of Medicine and Dentistry; and Alberto Espay, MD, PhD, the division director and Research Endowed Chair of the James J. and Joan A. Gardner Family Center for Parkinson's Disease and Movement Disorders, and a professor of clinical neurology and rehabilitation medicine at the University of Cincinnati. Looking for more Alzheimer disease discussion? Check out the NeurologyLive® dementia and Alzheimer disease clinical focus page. Episode Breakdown: 1:45 – Introduction and main findings 3:15 – Espay, with his perspective on the downstream effects of the approval 10:10 – Porsteinsson, with his perspective on the downstream effects of the approval 18:30 – Secondary end points and safety data 20:05 – Porsteinsson, on the recent progress in AD 23:05 – Espay, on contextualizing the effect of amyloid clearance 26:00 – Porsteinsson, on the logistics of the approval 34:20 – Espay, on the lingering unanswered questions 38:20 – Espay, on the communication of data to the public around the amyloid therapies 42:25 – Porsteinsson, on how things evolve going forward This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com. The stories and studies featured in this week's show, as well as additional expert interviews on lecanemab, can be found here: Show notes: Alberto Espay's lecanemab data infographic Lecanemab CLARITY data Donanameb TRAILBLAZER data Additional reading and coverage: FDA Grants Traditional Approval to Lecanemab as Therapy for Early-Stage Alzheimer Disease Medicare Expands Coverage for Fully Approved Alzheimer Agent Lecanemab Lecanemab to be Tested in Preclinical Alzheimer Disease Therapeutics Aim at Modifying Alzheimer Disease Additional expert interviews: David Bates, PhD: Downstream Impacts of Lecanemab on Alzheimer Disease, Future Drug Development Howard Fillit, MD: Lecanemab's Impact on Care and Diagnosis and the Future of Alzheimer Disease Treatment Nicole Fowler, PhD, MHSA: Preparing Primary Care Centers for New Wave of Alzheimer Agents Ronald C. Petersen, MD, PhD: Lessons Learned About Clinically Meaningful Benefit from Antiamyloid Trials Sharon Cohen, MD, FRCPC: Significance of Expanding Antiamyloid Therapy Class, Toolbox to Treat Alzheimer Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com. REFERENCES 1. FDA Converts Novel Alzheimer's Disease Treatment to Traditional Approval. FDA. News release. July 6, 2023. Accessed July 27, 2023. https://www.fda.gov/news-events/press-announcements/fda-converts-novel-alzheimers-disease-treatment-traditional-approval 2. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer's disease. N Engl J Med. 2023;388:9-21. doi:10.1056/NEJMoa2212948 3. Sims JR, Zimmer JA, Evans CD, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. Published online July 17, 2023. doi:10.1001/jama.2023.13239
In part 8 of our 9-part series on Parkinson's disease, Dr. Alberto Espay continues the discussion on genetic testing for Parkinson's Disease.
In part 9 of our 9-part series on Parkinson's disease, Dr. Alberto Espay discusses disease-modifying treatments for Parkinson's Disease.
In part 7 of our 9-part series on Parkinson's disease, Dr. Alberto Espay discusses genetic testing for Parkinson's Disease.
In part 6 of our 9-part series on Parkinson's disease, Dr. Alberto Espay discusses dystonias. This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.
In part 5 of our 9-part series, Dr. Alberto Espay continues discussing managing patients' symptoms while on Levodopa. This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.
In part 4 of our 9-part series, Dr. Alberto Espay discusses managing patients' symptoms while on Levodopa. This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.
In part 3 of our 9-part series, Dr. Alberto Espay discusses the use of extended-release drugs for the management of Parkinson's Disease. This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.
In part 2 of a 9-part series, Dr. Alberto Espay continues the discussion on the diagnosis of Parkinson's Disease using Levodopa. This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.
In part 1 of a 9-part series, Dr. Alberto Espay discusses the diagnosis of Parkinson's Disease using Levodopa. This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.
Boomer Living Tv - Podcast For Baby Boomers, Their Families & Professionals In Senior Living
Imagine for a moment that you are watching your loved one slowly deteriorate.They can no longer remember your name, what they did yesterday, what to do with their keys, or even how to brush their teeth. As the disease progresses, they become more and more withdrawn, until eventually, they can no longer recognize the faces of their loved ones. It's a heart-wrenching experience that I wouldn't wish on anyone.This is the reality for millions of people around the world who are affected by Alzheimer's disease. While there is no cure for Alzheimer's, there is hope. New research is providing insights into how we can better treat the disease.One such study has found that targeting amyloid beta could be more effective than previously thought.Amyloid-positive carriers of autosomal dominant Alzheimer's disease-causing mutations were put under observation for 3 years.The study found that higher levels of soluble Aβ42 predicted a lower risk of progression to cognitive impairment to a greater extent than lower levels of brain amyloid. In other words, it showed that treating Alzheimer's disease by targeting amyloid beta could be more effective than previously thought.This is an important finding that could change the way we approach Alzheimer's disease treatment in the future.For me, these hits close to home. My mother, mother-in-law, my brother-in-law, neighbor, sister's mother-in-law, and I have watched as the disease slowly robbed families of their memories, their ability to communicate, and eventually their mobility.To see that there might be a way to target the disease more effectively is very exciting. It gives me hope that one day we might be able to slow down or even stop the progression of Alzheimer's and Give people like me and your loved ones some of their precious memories back.Today my guest is Dr. Alberto Espay. Alberto Espay is a professor and endowed chair at the University of Cincinnati's James J. and Joan A. Gardner Center for Parkinson's disease.He has published over 300 peer-reviewed research articles and 8 books, including Common Movement Disorders Pitfalls and Brain Fables: The Hidden History of Neurodegenerative Diseases and a Blueprint to Conquer Them.Espay has served as Chair of the Movement Disorders Section of the American Academy of Neurology, Associate Editor of the Movement Disorders journal, and on the Executive Committee of the Parkinson Study Group. He recently launched the first biomarker study of aging (CCBPstudy.com).You can reach Alberto via these channels:email: mailto:alberto.espay@uc.eduLinkedIn: https://www.linkedin.com/in/alberto-espay-9a834758/
The lines between functional and organic are blurring, as a promising opportunity to develop outcome measurements arises. Dr. Alberto Espay discusses with Dr. Sara Schaefer these and other advancements in functional movement disorders.
Entrevista con el Dr. Alberto Espay, profesor de neurología en la Facultad de Medicina de la University of Cincinnati, director y presidente del James J. and Joan A. Centro Familiar Gardner para la Enfermedad de Parkinson y Trastornos del Movimiento en el Instituto de Neurociencia Gardner de la University of Cincinnati y un médico de Salud de la University of Cincinnati. En busca de más información para diversas poblaciones étnicas y raciales, los investigadores de la University of Cincinnati han estado realizando un estudio llamado Genética de los trastornos del movimiento inusuales y familiares desde 2017. Los investigadores de la Universidad de Cincinnati están ampliando un estudio para obtener más información sobre los marcadores genéticos de los trastornos del movimiento. Los trastornos del movimiento incluyen una gama de condiciones que afectan el sistema nervioso, y cada vez más se descubre que los trastornos más raros son causados por mutaciones genéticas. El diagnóstico genético es un elemento importante para los pacientes que buscan tratamiento para los trastornos del movimiento. Sin embargo, la mayoría de las pruebas genéticas y el conocimiento sobre los trastornos del movimiento se han centrado en las poblaciones europeas. A través de una asociación con la Universidad de Chile, el estudio ha crecido recientemente para ofrecer pruebas genéticas integrales para pacientes chilenos seleccionados con trastornos del movimiento raros de presunta naturaleza genética. Las pruebas de ADN relacionadas con la ascendencia disponibles para el público en general son relativamente económicas, pero las pruebas genéticas completas son costosas, por lo que es importante contar con fondos de investigación para cubrir las pruebas que pueden no ser asequibles para pacientes individuales. El Dr. Espay explica cómo los trastornos del movimiento incluyen una gama de condiciones que afectan el sistema nervioso, y cada vez más se descubre que los trastornos más raros son causados por mutaciones genéticas. Para el Dr. Espay "el origen del estudio y sobre la importancia de la equidad en las pruebas genéticas para los trastornos del movimiento raros." Los investigadores de la University of Cincinnati tienen planes para expandir a otra poblaciones y grupos étnicos para así poder mitigar la falta de diversidad en la investigación genética. Leer el artículo completo en https://www.uc.edu/news/articles/2022/03/uc-study-examines-genetics-of-movement-disorders.html
You have met Ben Stecher in episode #12 already – today we follow up on his very own account of deep brain stimulation after Ben has now lived with DBS to his subthalamic nucleus for 3 month. Ben is joined by Alberto Espay, who is a world-renowned expert on Parkinson's Disease from UC health in Cincinnati, Ohio. Together, Alberto and Ben wrote “Brain Fables”, a book with the aim to debunk some of the common (mis)conceptions in the field of neurodegenerative diseases. The book recently won the prose award by the Association of American Publishers in the category Neuroscience and is truly unique in its way to combine both the views of patient and health professional on the matter. We also touch upon a recent debate at the 2021 International Movement Disorders Congress (MDS) between Alberto Espay and Patrick Brundin, about the question whether clearing α-synuclein enough to treat Parkinson's disease. Alberto and Ben take us on a fascinating journey to think outside of the box, to question and challenge currently accepted views about the etiology of Parkinson's Disease and about their vision of how to conquer neurodegenerative diseases.
In the first part of the podcast, Dr. Alberto Espay talks with Prof. Julian Gillmore about CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. In the second segment, Dr. Pearce Korb discusses the long-term outcomes of osmotic demyelination syndrome in an updated cohort with Dr. Whitney Fitts.
Dr. Alberto Espay talks with Prof. Julian Gillmore about CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. Show references: https://www.nejm.org/doi/full/10.1056/NEJMoa2107454
Boomer Living Tv - Podcast For Baby Boomers, Their Families & Professionals In Senior Living
Amyloid-Beta And Alzheimer's Disease - Amyloid beta is a protein fragment that's been shown to play an important role in Alzheimer's disease.The Amyloid beta-protein is a major component of the plaques that form in many people with Alzheimer's disease. As these proteins clump together, they start to interfere and destroy neurons so research involving this protein has been intense; however, it seems as though there are more questions than answers when it comes to how amyloids cause neurodegeneration.Alzheimer's is the most common form of dementia. In 2021, Alzheimer's and other dementias will cost the nation $355 billion. By 2050, these costs could rise as high as $1.1 trillion. - according to alz.org.If you're like most people, you believe that amyloid plaques are the cause of Alzheimer's disease. The amyloid hypothesis is the leading theory for explaining Alzheimer's disease (AD) and it has been used to develop many drugs that have failed.The amyloid hypothesis, which states that plaques are causing cognitive impairment, has been the dominant theory for decades. Many scientists have spent their entire careers studying this theory and trying to prove it true. But now there is a growing group of scientists who question if this theory is correct or not.They found that while plaques do accumulate in the brains of people living with dementia, they aren't actually responsible for cognitive decline.--------------------Timestamps:[00:00] Introduction[00:02:37] Share with us a little bit about yourself?[00:03:57] What is so important about amyloid and how does amyloid interact with what we know about the brain?[00:08:56] How does the structure of this protein differ from other diseases associated with amyloid production?[00:11:32] Why are we just now discovering that amyloid plaques may be the symptom and not the cause of Alzheimer's?[00:16:33] What is the timeline like for cognitive progression for amyloid protein deposits?[00:21:53] Does this research mean that we will see any human trials in the future?[00:26:49] Do you recommend that people start to monitor their amyloid levels early like today, just in case they have early signs of memory loss?[00:31:53] Have you noticed cognitive improvements after being treated with drugs that lower amyloid levels?[00:35:11] Let's say if this theory is correct, what do you think the implications are for Alzheimer's patients and their families?[00:37:33] Did any of these studies mention what genetic factors or risk factors might be tied to?[00:39:51] Is there a link between gut health and Alzheimer's disease?[00:41:58] Do you think that there are ways for people with a family history of Alzheimer's disease to reduce their risk?[00:52:15] Do you have anything else that you would like to share?[00:53:08] How do people reach out to you?--------------------Bio:Dr. Alberto J. Espay is a Professor and the endowed chair of the University of Cincinnati James J. and Joan A. Gardner Family Center for Parkinson's Disease and Movement Disorders. His research efforts have focused on the measurement of motor and behavioral phenomena in—and clinical trials for—Parkinson's disease as well as in the understanding and management of functional movement disorders. Recently, he launched a phenotype-agnostic biomarker development program for neurodegenerative diseases with the aim to identify those small but biologically suitable subgroups most likely to respond to therapies already available or under current investigation.Learn more about Alberto:LinkedIn: https://www.linkedin.com/in/alberto-espay-9a834758/Website: https://www.uchealth.com/physician/alberto-espay/----------
Benjamin Stecher is doing impressive work in is role a scientific writer and patient advocate. He co-authored the book “Brain Fables” together with Alberto Espay, which recently won the prose award by the Association of American Publishers in the category Neuroscience. The book is truly unique in its way to combine both the views of patient and health professional on the history and misconceptions of Parkinson's Disease and what should change in our field to make progress. Benjamin was diagnosed with Parkinson's disease at 29. Since then, he left a successful managing partner position in Shanghai to study the disease full time. He has been traveling the world to witness the latest and greatest progress being made in over 100 research laboratories around the globe. He has interviewed over 80 international experts and shares his insights on the website tmrwedition.com. On June 2nd, Benjamin underwent deep brain stimulation surgery to the subthalamic nucleus. We are incredibly grateful that a mere nine days after that, he shares this experience lived from the most direct and intimate, the most important perspective: the one of the patient.
Only 29 when diagnosed with PD, Benjamin Stecher, co-authored the book Brain Fables. Brain Fables An estimated 80 million people live with a neurodegenerative disease, with this number expected to double by 2050. Despite decades of research and billions in funding there are no medications that can slow, much less stop, the progress of these diseases. The Time to rethink degenerative brain disorders has come. With no biological boundaries between neurodegenerative diseases, illnesses such as Parkinson's and Alzheimer's result from a large spectrum of biological abnormalities, hampering effective treatment. Acclaimed neurologist Dr Alberto Espay and Parkinson's advocate Benjamin Stecher present compelling evidence that these diseases should be targeted according to genetic and molecular signatures rather than clinical diagnoses. BRAIN FABLES is a wakeup call to the scientific community, explaining why we have no effective disease-modifying treatments, and how we can get on track
An estimated 80 million people live with a neurodegenerative disease, with this number expected to double by 2050. Despite decades of research and billions in funding, there are no medications that can slow, much less stop, the progress of these diseases. The time to rethink degenerative brain disorders has come. With no biological boundaries between neurodegenerative diseases, illnesses such as Parkinson's and Alzheimer's result from a large spectrum of biological abnormalities, hampering effective treatment. In Brain Fables: The Hidden History of Neurodegenerative Diseases and a Blueprint to Conquer Them (Cambridge UP, 2020), acclaimed neurologist Dr Alberto Espay and Parkinson's advocate Benjamin Stecher present compelling evidence that these diseases should be targeted according to genetic and molecular signatures rather than clinical diagnoses. There is no Parkinson's or Alzheimer's, simply people with Parkinson's or Alzheimer's. An incredibly important story never before told, Brain Fables is a wakeup call to the scientific community and society, explaining why we have no effective disease-modifying treatments, and how we can get back on track. Galina Limorenko is a doctoral candidate in Neuroscience with a focus on biochemistry and molecular biology of neurodegenerative diseases at EPFL in Switzerland. You can reach her at galina.limorenko@epfl.ch. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/neuroscience
An estimated 80 million people live with a neurodegenerative disease, with this number expected to double by 2050. Despite decades of research and billions in funding, there are no medications that can slow, much less stop, the progress of these diseases. The time to rethink degenerative brain disorders has come. With no biological boundaries between neurodegenerative diseases, illnesses such as Parkinson's and Alzheimer's result from a large spectrum of biological abnormalities, hampering effective treatment. In Brain Fables: The Hidden History of Neurodegenerative Diseases and a Blueprint to Conquer Them (Cambridge UP, 2020), acclaimed neurologist Dr Alberto Espay and Parkinson's advocate Benjamin Stecher present compelling evidence that these diseases should be targeted according to genetic and molecular signatures rather than clinical diagnoses. There is no Parkinson's or Alzheimer's, simply people with Parkinson's or Alzheimer's. An incredibly important story never before told, Brain Fables is a wakeup call to the scientific community and society, explaining why we have no effective disease-modifying treatments, and how we can get back on track. Galina Limorenko is a doctoral candidate in Neuroscience with a focus on biochemistry and molecular biology of neurodegenerative diseases at EPFL in Switzerland. You can reach her at galina.limorenko@epfl.ch. Learn more about your ad choices. Visit megaphone.fm/adchoices
An estimated 80 million people live with a neurodegenerative disease, with this number expected to double by 2050. Despite decades of research and billions in funding, there are no medications that can slow, much less stop, the progress of these diseases. The time to rethink degenerative brain disorders has come. With no biological boundaries between neurodegenerative diseases, illnesses such as Parkinson's and Alzheimer's result from a large spectrum of biological abnormalities, hampering effective treatment. In Brain Fables: The Hidden History of Neurodegenerative Diseases and a Blueprint to Conquer Them (Cambridge UP, 2020), acclaimed neurologist Dr Alberto Espay and Parkinson's advocate Benjamin Stecher present compelling evidence that these diseases should be targeted according to genetic and molecular signatures rather than clinical diagnoses. There is no Parkinson's or Alzheimer's, simply people with Parkinson's or Alzheimer's. An incredibly important story never before told, Brain Fables is a wakeup call to the scientific community and society, explaining why we have no effective disease-modifying treatments, and how we can get back on track. Galina Limorenko is a doctoral candidate in Neuroscience with a focus on biochemistry and molecular biology of neurodegenerative diseases at EPFL in Switzerland. You can reach her at galina.limorenko@epfl.ch.
An estimated 80 million people live with a neurodegenerative disease, with this number expected to double by 2050. Despite decades of research and billions in funding, there are no medications that can slow, much less stop, the progress of these diseases. The time to rethink degenerative brain disorders has come. With no biological boundaries between neurodegenerative diseases, illnesses such as Parkinson's and Alzheimer's result from a large spectrum of biological abnormalities, hampering effective treatment. In Brain Fables: The Hidden History of Neurodegenerative Diseases and a Blueprint to Conquer Them (Cambridge UP, 2020), acclaimed neurologist Dr Alberto Espay and Parkinson's advocate Benjamin Stecher present compelling evidence that these diseases should be targeted according to genetic and molecular signatures rather than clinical diagnoses. There is no Parkinson's or Alzheimer's, simply people with Parkinson's or Alzheimer's. An incredibly important story never before told, Brain Fables is a wakeup call to the scientific community and society, explaining why we have no effective disease-modifying treatments, and how we can get back on track. Galina Limorenko is a doctoral candidate in Neuroscience with a focus on biochemistry and molecular biology of neurodegenerative diseases at EPFL in Switzerland. You can reach her at galina.limorenko@epfl.ch. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/psychology
An estimated 80 million people live with a neurodegenerative disease, with this number expected to double by 2050. Despite decades of research and billions in funding, there are no medications that can slow, much less stop, the progress of these diseases. The time to rethink degenerative brain disorders has come. With no biological boundaries between neurodegenerative diseases, illnesses such as Parkinson's and Alzheimer's result from a large spectrum of biological abnormalities, hampering effective treatment. In Brain Fables: The Hidden History of Neurodegenerative Diseases and a Blueprint to Conquer Them (Cambridge UP, 2020), acclaimed neurologist Dr Alberto Espay and Parkinson's advocate Benjamin Stecher present compelling evidence that these diseases should be targeted according to genetic and molecular signatures rather than clinical diagnoses. There is no Parkinson's or Alzheimer's, simply people with Parkinson's or Alzheimer's. An incredibly important story never before told, Brain Fables is a wakeup call to the scientific community and society, explaining why we have no effective disease-modifying treatments, and how we can get back on track. Galina Limorenko is a doctoral candidate in Neuroscience with a focus on biochemistry and molecular biology of neurodegenerative diseases at EPFL in Switzerland. You can reach her at galina.limorenko@epfl.ch. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/medicine
An estimated 80 million people live with a neurodegenerative disease, with this number expected to double by 2050. Despite decades of research and billions in funding, there are no medications that can slow, much less stop, the progress of these diseases. The time to rethink degenerative brain disorders has come. With no biological boundaries between neurodegenerative diseases, illnesses such as Parkinson's and Alzheimer's result from a large spectrum of biological abnormalities, hampering effective treatment. In Brain Fables: The Hidden History of Neurodegenerative Diseases and a Blueprint to Conquer Them (Cambridge UP, 2020), acclaimed neurologist Dr Alberto Espay and Parkinson's advocate Benjamin Stecher present compelling evidence that these diseases should be targeted according to genetic and molecular signatures rather than clinical diagnoses. There is no Parkinson's or Alzheimer's, simply people with Parkinson's or Alzheimer's. An incredibly important story never before told, Brain Fables is a wakeup call to the scientific community and society, explaining why we have no effective disease-modifying treatments, and how we can get back on track. Galina Limorenko is a doctoral candidate in Neuroscience with a focus on biochemistry and molecular biology of neurodegenerative diseases at EPFL in Switzerland. You can reach her at galina.limorenko@epfl.ch. Learn more about your ad choices. Visit megaphone.fm/adchoices
An estimated 80 million people live with a neurodegenerative disease, with this number expected to double by 2050. Despite decades of research and billions in funding, there are no medications that can slow, much less stop, the progress of these diseases. The time to rethink degenerative brain disorders has come. With no biological boundaries between neurodegenerative diseases, illnesses such as Parkinson's and Alzheimer's result from a large spectrum of biological abnormalities, hampering effective treatment. In Brain Fables: The Hidden History of Neurodegenerative Diseases and a Blueprint to Conquer Them (Cambridge UP, 2020), acclaimed neurologist Dr Alberto Espay and Parkinson's advocate Benjamin Stecher present compelling evidence that these diseases should be targeted according to genetic and molecular signatures rather than clinical diagnoses. There is no Parkinson's or Alzheimer's, simply people with Parkinson's or Alzheimer's. An incredibly important story never before told, Brain Fables is a wakeup call to the scientific community and society, explaining why we have no effective disease-modifying treatments, and how we can get back on track. Galina Limorenko is a doctoral candidate in Neuroscience with a focus on biochemistry and molecular biology of neurodegenerative diseases at EPFL in Switzerland. You can reach her at galina.limorenko@epfl.ch. Learn more about your ad choices. Visit megaphone.fm/adchoices
An estimated 80 million people live with a neurodegenerative disease, with this number expected to double by 2050. Despite decades of research and billions in funding, there are no medications that can slow, much less stop, the progress of these diseases. The time to rethink degenerative brain disorders has come. With no biological boundaries between neurodegenerative diseases, illnesses such as Parkinson's and Alzheimer's result from a large spectrum of biological abnormalities, hampering effective treatment. In Brain Fables: The Hidden History of Neurodegenerative Diseases and a Blueprint to Conquer Them (Cambridge UP, 2020), acclaimed neurologist Dr Alberto Espay and Parkinson's advocate Benjamin Stecher present compelling evidence that these diseases should be targeted according to genetic and molecular signatures rather than clinical diagnoses. There is no Parkinson's or Alzheimer's, simply people with Parkinson's or Alzheimer's. An incredibly important story never before told, Brain Fables is a wakeup call to the scientific community and society, explaining why we have no effective disease-modifying treatments, and how we can get back on track. Galina Limorenko is a doctoral candidate in Neuroscience with a focus on biochemistry and molecular biology of neurodegenerative diseases at EPFL in Switzerland. You can reach her at galina.limorenko@epfl.ch. Learn more about your ad choices. Visit megaphone.fm/adchoices
Dr. Alberto Espay is a Professor of Neurology and the Director of the James J. and Joan A. Gardner Family Center for Parkinson’s Disease and Movement Disorder. Dr. Espay got his MD from the Central University of Venezuala, received his residency training at Indiana University, and fellowship at the University of Toronto. He is also the author of the book “Brain Fables: The Hidden History of Neurodegenerative Diseases and a Blueprint to Conquer Them” released just this month in the United States. Today, we discuss a broad range of topics with Dr. Espay, from the structures in place to fund and advance science and scientific careers, to his own experiences navigating that system, to his excitement and frustrations with his field of neurodegenerative disease. Credits: Our thanks to Dr. Espay for being on the podcast. Follow Dr. Espay on Twitter: @AlbertoEspay Dr. Espay’s Faculty Page: https://www.uchealth.com/physician/alberto-espay/ Pick up a copy of “Brain Fables” here: https://www.amazon.com/dp/B088T85GMF/ref=cm_sw_r_tw_dp_x_ka7qFbM9JDNE9 Host: Bejan Saeedi Co-Host and Audio Engineer – Joe Behnke Executive Producer, Social Media Coordinator, and BTMblog Editor-in-Chief – Carey Jansen Executive Producer – Michael Sayegh Faculty Advisor – Dr. Brian Robinson Twitter: @behindthescope_ Instagram: @behindthemicroscopepod Facebook: @behindthemicroscope1 Website: behindthemicroscope.com
Dr. Alberto Espay, MD discusses the future of Parkinson's disease research.
In the first segment, Dr. Jeff Ratliff talks with Dr. Nico Dosenbach about his Neuron paper on neural networks and deep brain stimulation, and they specifically cover the Neurology Today article on this paper with respect to the impact on DBS. In the second part of the podcast, Dr. Jeff Ratliff speaks with Dr. Alberto Espay about his paper—from the March 17th issue of Neurology—on reconsidering biomarkers in Parkinson disease. You can read the Neurology Today story here: https://bit.ly/2TzJr0Y; and you can read the Neuron paper here: https://bit.ly/2TX1zku. Disclosures can be found at Neurology.org. CME Opportunity: Listen to this week’s Neurology Podcast and earn 0.5 AMA PRA Category 1 CME Credits™ by answering the multiple-choice questions in the online Podcast quiz.
While Parkinson’s disease (PD) is a broad category that includes similar symptoms, each person’s disease may have different features, rate of progression, needs and treatments connected to the specific underlying cause of that person’s disease. As we move towards “personalized” or “precision medicine,” which strives to treat each person’s condition according to their unique disease, research in neurology needs the tools to be able to define differences that can allow a truly personalized approach to treatment. Measuring biomarkers, measurable features that are characteristic of a disease, is one of these tools that provides a better understanding of the disease’s underlying biology and causes. They could be imaging such as MRI, chemicals in the blood or brain, brain wave patterns, or even specific signs and symptoms. Knowing the underlying causes of the disease can help to design and test therapies that could slow down or stop PD. Using biomarkers would be especially helpful for the design of clinical trials for several reasons. It would allow researchers to segment testing of medications by individuals with similar underlying biology in order to understand if it works for all or just some types of Parkinson’s. It would also help us better monitor if and how a drug is working. Neurologist Dr. Alberto Espay of the University of Cincinnati proposes that Parkinson’s research requires a new way of thinking based on biomarkers to know precisely what kind of disease one is dealing with, especially when participating in clinical trials. Drugs that work for one form of PD may not work for another. Dr. Espay compares the precision of treating Parkinson’s today to where the cancer field was 30 years ago.
For the September 2018 Delayed Recall episode, we are featuring recordings of in-person interviews that took place at the April 2018 AAN Annual Meeting. All interviewees were plenary speakers who gave talks throughout Annual Meeting week. These recordings originally appeared as “What’s Trending” segments in July 2018 (July 17, 24, and 31, respectively). In the first interview, we will hear Dr. Alberto Espay speak with Dr. Jeff Lichtman about connectomics. Next, Dr. Stacey Clardy interviews Dr. Michael Wilson about his talk on next-generation sequencing and diagnosing meningitis and encephalitis. Last, Dr. Alberto Espay discusses the matter of who should be the primary caregivers for functional disorder patients with Dr. Andrea Leigh Haller and Dr. David Perez.
1. Organic solvents and MS susceptibility: Interaction with MS risk HLA genes 2. AAN 2018 Controversies in Neurology plenary: Andrea Leigh Haller and David Perez discuss primary caregivers for functional disorder patientsDr. Stacey Clardy talks with Dr. Anna Hedström about her paper on exposure to organic solvents and the associated risk of developing multiple sclerosis, followed by a discussion with Dr. Alberto Espay, Dr. Andrea Leigh Haller, and Dr. David Perez on who should be the primary caregivers for functional disorder patients. The second interview was originally recorded at the AAN Annual Meeting in Los Angeles.DISCLOSURES: Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR). Drs. Hedström, Leigh Haller, and Perez report no disclosures. Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; and receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation, and the NIH.
1. Featured Article: Longitudinal analysis of impulse control disorders in Parkinson disease2. What's Trending: Frontiers in Neuroscience plenary interview from 2018 Annual MeetingThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the July 17, 2018 issue of Neurology. In the first segment, Dr. Jason Crowell talks with Dr. Alexis Elbaz about his paper on impulse control disorders in Parkinson disease. In the second part of the podcast, Dr. Alberto Espay focuses his interview with Dr. Jeff Lichtman on connectomics. The interview was recorded at the 2018 AAN Annual Meeting in Los Angeles.DISCLOSURES: Drs. Crowell and Lichtman reports no disclosures. Dr. Elbaz has received research support from Agence nationale de la recherche (ANR), Agence nationale de sécurité du médicament et des produits de santé, JPND (Joint Programme - Neurodegenerative Disease Research), Institut de santé publique (IRESP), French ministry of agriculture, and Anses (government agency for food and environment safety). Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.
Patient Perspectives, Part II (January 2018)This month’s Delayed Recall episode is the second part of our feature including interviews that focus on the patient perspective. The first part of this feature aired as the Delayed Recall episode for December 2017. We feature four interviews in this second installment; the first is Dr. Alberto Espay’s interview with Dr. Ted Burns in the Sept. 3, 2013 episode, in which they discuss Dr. Burns’ cancer diagnosis and his subsequent experience as a patient. In the second interview, with Dr. Lara Marcuse, Dr. Marcuse responds to Dr. Espay’s Sept. 2013 interview with Dr. Burns, and remarks briefly on her own time as a patient. This interview was part of the October 29, 2013 episode. The third interview features Dr. Espay and Dr. Burns once more; they discuss Dr. Burns’ cancer recurrence, as well as Dr. Burns’ view about the kind of care that he believes is important for healthcare providers to focus on. This interview first appeared in the August 1, 2017 episode. Last, we feature an interview from the June 3, 2008 episode, between Dr. Ted Burns and Dr. Bob Joynt, in which Dr. Joynt offers his advice regarding patient treatment.
Show description/summary:1) Quality improvement in neurology: Stroke and stroke rehabilitation quality measurement set update2) Neurology Today® paper on Parkinson disease and autoimmunityIn the first segment, Dr. Dan Ackerman talks with Dr. Gene Latorre about his paper on the updated quality measurement set for stroke and stroke rehabilitation. In the second part of the podcast, Dr. Alberto Espay focuses his interview with Dr. David Sulzer on Parkinson disease and autoimmunity. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.All other participants report no disclosures.
Show description/summary:1) On being sick: Musings about kindness, side effects, and slowing down2) Resident & Fellow Section Update: Annual Writing AwardIn the first segment, Dr. Alberto Espay talks with Dr. Ted Burns about his Special Editorial, “On being sick: Musings about kindness, side effects, and slowing down.” In the second part of the podcast, Dr. Andy Southerland focuses his interview with Dr. John Millichap on the annual Resident & Fellow writing award. Disclosures can be found at Neurology.org.DISCLOSURES:Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. All other participants report no disclosures.Dr. Southerland serves as Podcast Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review.Dr. Millichap has received speaker honoraria from Invitae; serves on the editorial board for Neurology and Pediatric Neurology Briefs; receives publishing royalties from BMJ Best Practice and UpToDate; and has received research support from UCB Pharma, Thrasher Research Fund, and Citizens United for Research in Epilepsy.
How can we bring Parkinson’s disease into the age of personalized medicine? One such approach recently described by Alberto Espay (University of Cincinnati, OH, USA) is to subtype the disease according to the presence of certain biomarkers. This is an approach that he says could “up the ante in our ability to modify the disease”, moving us away from purely dopaminergic strategies that address only the ‘common denominator’ of the disease. We caught up with Dr Espay at the American Academy of Neurology Annual Meeting (Boston, MA, USA, 22–28 April), where he told us more about his call for a biomarker-driven approach to subtyping Parkinson’s, and how this could change the way we both research and treat the disease. You can find more podcasts, as well as the latest news and expert opinions across neuroscience and neurology, at www.neuro-central.com
Show description/summary:1) A randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study2) What's Trending: Survival and dementia in GBA-associated Parkinson disease This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the May 23, 2017 issue of Neurology. In the first segment, Dr. Matthew Barrett interviews Dr. Hubert Fernandez about his paper on deutetrabenazine for tardive dyskinesia. For our “What's Trending” feature of the week, Dr. Alberto Espay talks with Dr. Roberto Cilia about his Annals of Neurology paper on survival and dementia in GBA-associated Parkinson disease. Disclosures can be found at Neurology.org. Disclosures can be found at Neurology.org. DISCLOSURES:Dr. Barrett receives research support from Axovant Sciences, Inc., Azevan Pharmaceuticals, Merck Sharp & Dohme Corp, Virginia Center of Alzheimer´s and Related Diseases, Department of Defense Neurotoxin Exposure Treatment Parkinson's Research Program, and NIH.Dr. Fernandez serves on scientific advisory boards for Solvay Duodopa Global Study, EMD Serono Safinamide Global Study, and the Xeomin Registry (all uncompensated); has received travel or speaker honoraria from USF CME, Cleveland Clinic CME, Medical Communications Media, Health Professions Conferencing, Ipsen, Merz Pharmaceuticals, US World Meds, Prime Education Inc., Ohio State University, International Parkinson and Movement Disorders Society, Carline Communications, Medscape, Biogen GE Healthcare, Lundbeck, and Pfizer; served as Medical Editor for the Movement Disorders Society; co-owns the patent for COMPRESS; receives royalty payments from book publications with Demos Publishing, Manson Publishing, and Springer Publishing; has received research support from AbbVie, Acadia, Teva Pharmaceuticals, Biotie Therapeutics, Civitas, Kyowa Kirin International, Rhythm Pharmaceuticals, Synosia Therapeutics, Abbott, Merz Pharmaceuticals, Xeomin Registry Study, Ipsen Pharmaceuticals, Michael J. Fox Foundation, Movement Disorders Society, Huntington Study Group, Parkinson Study Group, National Parkinson Foundation, Society of Progressive Supranuclear Palsy, and NIH/NINDS.Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.Dr. Cilia receives research support from Fondazione Grigioni per il Morbo di Parkinson.
Show description/summary:1) Serum neurofilament light chain as a biomarker for mild traumatic brain injury in contact sports2) What's Trending: Biomarker validation and precision medicine in Parkinson disease.This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the May 9, 2017 issue of Neurology. In the first segment, Dr. Kristen Heinan talks with Dr. Pashtun Shahim about his paper on serum neurofilament light chain as a biomarker for mild traumatic brain injury in contact sports. In the next part of the podcast Dr. Alberto Espay focuses his discussion with Dr. David Standaert on biomarker validation and precision medicine in Parkinson disease. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.Dr. Standaert serves on scientific advisory boards for the American Parkinson Disease Association; serves on the DSMB for Shire/Biropharma; received honoraria from the Movement Disorder Society and Georgia Regents University; is Associate Editor for Movement Disorders; receives publishing royalties for Movement Disorders (McGraw-Hill Publishers, 3rd ed.); consulted for Serina Therapeutics, Kirchner Group, Teva Neuroscience, Abbvie, and the U.S. Attorney's Office; receives research support from Abbvie, Acerta Pharmaceuticals, Ceregene, Quintiles, NIH, Alabama Department of Commerce, American Parkinson Disease Association, Michael J. Fox Foundation for Parkinson Research, Bachmann-Strauss Dystonia & Parkinson Foundation, and the Dystonia Medical Research Foundation.All other participants report no disclosures.
Show description/summary:1) Reduction in Time to Treatment in Pre-hospital Telemedicine Evaluation and Thrombolysis2) What's Trending: gut microbiota regulate motor deficits and neuroinflammation in Parkinson diseaseOur podcast has changed to a two-segment format! Enjoy two in-depth interviews each week, starting with one featured article from the Neurology® family of journals followed by an interview on a trending topic or on a notable article from Neurology Today.This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the April 4, 2017 issue of Neurology. In the first segment, Dr. Andy Southerland interviews Dr. Shazam Hussain about his paper on time-to-treatment in pre-hospital telemedicine evaluation and thrombolysis. Then, for our “What's Trending” feature of the week, Dr. Alberto Espay talks with Dr. Sarkis Mazmanian about his paper on how gut microbiota regulate motor deficits and neuroinflammation in Parkinson Disease. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review.Dr. Hussain served on scientific advisory boards for pulsar neurovascular, penumbra, Inc., and Prolong Medical.Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.For full disclosures, please contact Dr. Mazmanian directly at sarkis [at] caltech.edu.
The first interview is with Dr. Jeff Ratliff and Dr. Kailash Bhatia on the topic of dystonia. The second is with Dr. Alberto Espay and Dr. Roger Elble on tremor. These interviews were first released on November 1 and November 8, 2016. In the third week's interview, originally released on November 15, 2016, Dr. Alberto Espay interviews Don Gilbert on tics. In the fourth interview, from November 22, 2016, Dr. Ratliff speaks with Dr. Ruth Walker about chorea. The fifth and final interview, originally released on November 29, 2016, is an interview with Dr. Espay and Dr. Steven Frucht on the topic of myoclonus.
1) Practice advisory: The utility of EEG theta/beta power ration in ADHD diagnosis2) e-Pearl topic: Hemiplegic migraine3) Topic of the month: How to examine and approach movement disordersThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Adam Numis interviews Dr. David Gloss about this AAN Practice Advisory paper on the utility of EEG theta and beta power ration in attention deficit hyperactivity disorder diagnosis. Dr. Ilena George is reading our e-Pearl of the week about hemiplegic migraine. In the next part of the podcast Dr. Alberto Espay interviews Dr. Steven Frucht on the topic of “how to approach” myoclonus.DISCLOSURES: Dr. Numis served on the editorial team for the Neurology® Resident and Fellow Section. Dr. Gloss serves on the Level of evidence team for Neurology®; is an Evidence-based medicine consultant for the American Academy of Neurology; receives royalties from the publication of the book Neurology for the Specialty Boards.Dr. George serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.Dr. Frucht serves as Editor-in-Chief for the Journal of Clinical Movement Disorders; is a consultant for UCB; received speaker honoraria from Merz Pharmaceuticals, LLC and Impax; receives royalties from the publication of the book Movement Disorders Emergencies; and is employed by the American Academy of Neurology Movement Disorders Society.
1) Efficacy and safety of deflazacort versus prednisone and placebo for Duchenne muscular dystrophy2) e-Pearl topic: Alien limb phenomenon3) Topic of the month: How to examine and approach movement disordersThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Kelly Gwathmey interviews Dr. Robert Griggs about his the efficacy and safety of deflazacort versus prednisone for boys with Duchenne muscular dystrophy. Dr. Ilena George is reading our e-Pearl of the week about alien limb phenomenon. In the next part of the podcast Dr. Alberto Espay interviews Dr. Don Gilbert on the topic of tics.DISCLOSURES: Dr. Griggs serves as Correspondence Editor for Neurology®; serves as an editorial board member of NeuroTherapeutics and Current Treatment Opinions in Neurology; serves on the scientific advisory board for SAB for National Hospital Queen Square, Marathon Pharmaceuticals, PTC Therapeutics, Inc., DSMB, Taro Pharm and Sarepta Pharmaceuticals; is a consultant for Marathon, PTC Therapeutics, Sarepta, Taro Pharm and Idera Pharmaceuticals;receives royalties for data of previous studies from Taro Pharm and Marathon Pharmaceuticals; receives royalties from the publication of the books: Andreoli and Carpenter's Cecil Essentials of Medicine, Eighth Edition, Cecil Textbook of Medicine, multiple editions and Evaluation and Treatment of Myopathies; receives research support from Taro Pharma, Marathon Pharmaceuticals, Parent Project Muscular Dystrophy, Inc., Muscular Dystrophy Association, Novel Molecular Mechanisms of Neuromuscular Disease: Implications for Therapy and the NIH.Dr. George serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.Dr. Gilbert serves on the scientific advisory boards of Investigations of Neuroplasticity Mechanisms in Autism Spectrum Disorders, the Berenson-Allen Center for Noninvasive Brain Stimulation, and Beth Israel Deaconess Medical Center; received honoraria from the Tourette Association of America, the Centers for Disease Control and Prevention, and the Hong Kong Society of Child Neurology and Developmental Pediatrics; received funding for travel for educational talks to physicians and affected patients and families;receives royalties from the publication of the book Movement Disorders in Childhood, 2nd edition; receives research support from Ecopipam Pharmaceuticals, Neurocrine Pharmaceuticals, EryDel Pharmaceuticals, and NIH; and has provided expert testimony for the Health Resources and Services Administration, Department of Health and Human Services regarding Division of Vaccine Injury Compensation Programs.
1) Progression of brain atrophy in PSP and CBS over six months and one year2) What's Trending: Interview with Mike Amery about Medicare Sustainable Growth Rate repeal and the Medicare Access and CHIP Reauthorization Act 3) Topic of the month: How to examine and approach movement disordersThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. John Morgan interviews Dr. Adam Boxer about his paper about on progression of brain atrophy in progressive supranuclear palsy and corticobasal syndrome. Dr. Ted Burns is interviewing Mike Amery for our “What's Trending” feature of the week about Medicare Sustainable Growth Rate repeal and the Medicare Access and CHIP Reauthorization Act. In the next part of the podcast Dr. Alberto Espay interviews Dr. Rodger Elble on the topic of “how to approach” tremor disorders.DISCLOSURES: Dr. Morgan is a consultant for Impax, Lundbeck Inc., National Parkinson Foundation, Teva Pharmaceutical Industries Ltd., and Veloxis; serves on the speakers' bureau of Impax and Teva Pharmaceutical Industries Ltd.; received compensation for review of medical records and expert witness testimony in multiple cases of litigation involving neurologic co; receives research support from National Parkinson Foundation, Parkinson's Outcome Project Grant and the NIH.Dr. Boxer serves on the scientific advisory board for Alector, Asceneuron and Delos; received funding for travel from the International Society for CNS Clinical Trials Methodology, the Movement Disorders Society, the Association for Frontotemporal Degeneration, Fidelity Biosciences Research Institute and the Tau Consortium; is a consultant for Abbvie, Ionis, Janssen and Merck Serono; holds stock options in Alector and Delos; receives research support from Avid, Biogen Idec, BMS, C2N, Cortice, Forum, Genentech, Inc., Janssen, Pfizer Inc, Eli Lilly and Company, Roche, TauRx, The Tau Research Consortium, the Bluefield Project, Corticobasal Degeneration Solutions, the Alzheimer's Association and the NIH.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Amery is employed as Legislative Counsel for the American Academy of Neurology.Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.Dr. Elble receives research support from GlaxoSmithKline, Teva Pharmaceutical Industries Ltd., Phytopharm, Pfizer Inc, Ortho-McNeil, Spastic Paralysis Research Foundation of Kiwanis International, Illinois-Eastern Iowa District and the NIH.
1) Zika virus-associated Guillain-Barre Syndrome Variant in Haiti2 e-Pearl topic: Juvenile Huntington Disease3) Topic of the month: Clinical Trials Plenary Session at the AAN meeting about 5-HT6 antagonist as adjunctive therapy to cholinesterase inhibitors in patients with mild-to-moderate Alzheimer diseaseThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Stephen Donahue interviews Dr. Aaron Berkowitz about his paper on Zika virus-associated Guillain-Barre syndrome variant in Haiti. Dr. Ilena George is reading our e-Pearl of the week about juvenile Huntington disease. Dr. Alberto Espay interviews Dr. Alireza Atri about his Clinical Trials Plenary Session at the AAN meeting about 5-HT6 antagonist as adjunctive therapy to cholinesterase inhibitors in patients with mild-to-moderate Alzheimer disease.DISCLOSURES: Dr. Berkowitz receives royalties from the publication of the book: Clinical Pathophysiology Made Ridiculously Simple and the book: The Improvising Mind; received funding for travel from Stevens Institute of Technology; received speaker honorarium from Audio Digest; and received honorarium for recorded CME lecture.Dr. George serves on the editorial team for the Neurology® Resident and Fellow Section.Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.
1) Neurology® Clinical Practice: Alice in Wonderland syndrome: a systematic review2) What's Trending: Interview with Clinton Wright about his paper on leisure time physical activity and how it is associated with cognitive decline3) Topic of the month: Frontiers in Neuroscience Plenary Session at the AAN meeting about the implications for neurology and psychiatry in the treatment of cerebellar cognitive affective syndromeThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. David Lapides interviews Dr. Jan Dirk Blom about his Neurology: Clinical Practice paper on the Alice in Wonderland syndrome. Dr. Ted Burns is interviewing Dr. Clinton Wright for our “What's Trending” feature of the week about his paper on leisure time physical activity and how it is associated with cognitive decline. Dr. Alberto Espay interviews Dr. Jeremy Schmahmann about his Frontiers in Neuroscience Plenary Session at the AAN meeting about the implications for neurology and psychiatry in the treatment of cerebellar cognitive affective syndrome.DISCLOSURES: Dr. Blom receives royalties from the publication of the book Hallucinations, Research and Practice and the book A Dictionary of Hallucinations.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Wright receives royalties from UpToDate website for two chapters on vascular dementia; receives research support from American Stroke Association-Bugher Foundation Centers of Excellence project and the NIH.Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as aneditorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnologies, Michael J. Fox Foundation and the NIH.Dr. Schmahmann serves as an editorial board member of The Cerebellum and its sister journal, Cerebellum and Ataxias; serves on the scientific advisory board for Ataxion, Inc. and Atlas Ventures; Receives royalties from the publications of the books: The Cerebellum and Cognition: International Review of Neurobiology, MRI Atlas of the Human Cerebellum, Pathways of the Brain, Cerebellar Disorders in Children: Clinics in Development Medicine, and Handbook of the Cerebellum and Cerebellar Disorders; is a consultant for Takeda Pharmaceutical Company Limited; holds stock option in Ataxion, Inc. and Atlas Ventures; receives research support from Birmingham Foundation, MINDlink Foundation, Sidney R. Baer Jr., Foundation, National Ataxia Foundation, Ataxia Telangiectasia Children's Project and the NIH.NO CME WILL BE OFFERED THIS WEEK.
1) Low-cost, tablet-based option for prehospital neurologic assessment: the iTREAT Study2) What's Trending: Interview with Dafne Horovitz about her paper on cranial bone collapse in microcephalic infants prenatally exposed to Zika virus infection3) Topic of the month: Controversies in Neurology Plenary Session at the AAN meeting about the pro and con effects of cognitive enhancing activities and their effects on preventing dementiaThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Kevin Barrett interviews Dr. Andy Southerland about his paper on a low-cost, tablet-based option for prehospital neurologic assessment. Dr. Ted Burns is interviewing Dr. Dafne Horovitz for our “What's Trending” feature of the week about her paper on cranial bone collapse in microcephalic infants prenatally exposed to Zika virus infection. Dr. Alberto Espay interviews Drs. Dave Knopman and Kaycee Sink about their Controversies in Neurology Plenary Session at the AAN meeting about the pro and con effects of cognitive enhancing activities and their effects on preventing dementia.DISCLOSURES: Dr. Barrett serves as Associate Editor for Neurohospitalist; serves as an editorial board member for Neurology®; receives royalties from the publications of the books Stroke and Neurology in Practice [Edited book]; and receives research support from the NIH.Dr. Southerland serves as Podcast Deputy Editor for Neurology®; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Horovitz serves as Associate Editor for Journal of Community Genetics; received speaker honoraria from Biomarin Pharmaceutical, Genzyme-Sanofi, Shire Pharmaceuticals, Inc. and Alexion Pharmaceuticals, Inc.; received funding for travel to medical meeting from Genzyme-Sanofi and Shire Pharmaceuticals, Inc.Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.Dr. Knopman serves on the scientific advisory board for Consultant Bluefield project, Lundbeck Pharmaceuticals Inc., DIAN study DSMB; served as Associate Editor for Neurology® until October 2015; receives research support from the NIH, Mayo Alzheimer's Disease Research Center, Mayo Alzheimer Disease Patient Registry, ARIC Dementia Study and Chronic Kidney Disease and Cognitive functioning; received funding for travel to two lectures Alzheimer Conference, Seoul Korea and Behavioral Neurology Conference, Hyderabad, India.Dr. Sink served on the data safety monitoring board for two NIH funded clinical trials; initiated grants from the Alzheimer's Association and the Donald W. Reynolds Foundation as an investigator; received research support from the NIH.